{"id":"NCT01328379","sponsor":"Acorda Therapeutics","briefTitle":"Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis","officialTitle":"Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Two Doses of Oral Dalfampridine Extended Release Tablets (5 mg and 10 mg Twice Daily) in Patients With Multiple Sclerosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-03","primaryCompletion":"2012-04","completion":"2012-07","firstPosted":"2011-04-04","resultsPosted":"2013-08-13","lastUpdate":"2013-09-05"},"enrollment":430,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Sclerosis"],"interventions":[{"type":"DRUG","name":"Dalfampridine-ER 5mg","otherNames":["Fampridine, Dalfampridine, Ampyra"]},{"type":"DRUG","name":"Dalfampridine-ER 10mg","otherNames":["Fampridine, Dalfampridine, Ampyra"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Dalfampridine-ER 5mg","type":"ACTIVE_COMPARATOR"},{"label":"Dalfampridine-ER 10mg","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to investigate the safety and efficacy of a lower dose of dalfampridine extended release tablets compared to the currently approved dose in improving walking in Multiple Sclerosis (MS) patients.","primaryOutcome":{"measure":"Change From Baseline in Walking Speed Near Maximum Plasma Concentration at Steady State (CmaxSS) of Placebo and Dalfampridine-ER (5mg and 10mg), Using the Timed 25 Foot Walk (T25FW).","timeFrame":"Baseline Visit 1 (double-blind study day 1) and approximately 3-4 hours post dose at Visit 3 (end of double-blind week 4)","effectByArm":[{"arm":"Placebo","deltaMin":0.363,"sd":0.0511},{"arm":"Dalfampridine-ER 5mg","deltaMin":0.423,"sd":0.047},{"arm":"Dalfampridine-ER 10mg","deltaMin":0.478,"sd":0.0569}],"pValues":[{"comp":"OG000 vs OG001","p":"0.457"},{"comp":"OG000 vs OG002","p":"0.107"},{"comp":"OG001 vs OG002","p":"0.375"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":17},"locations":{"siteCount":70,"countries":["United States"]},"refs":{"pmids":["26565077","25560174"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":143},"commonTop":["Headache","Urinary tract infection","Nausea","Dizziness","Insomnia"]}}